Furthermore, reduced CYP2C9 activity is associated with higher drug exposure and increased risk of gastrointestinal bleeding, hypertension and myocardial infarction upon treatment with multiple NSAIDs, including oxicams, celecoxib, flurbiprofen and ibuprofen [39–42]. This evidence concerns the gene CYP2C9 and myocardial infarction.